ReachMD

Dr. Judith Hochman is the Harold Snyder Family Professor of Cardiology, clinical chief of cardiology, director of the Cardiovascular Clinical Research Center and co-director of the NYU-HHC Clinical Translational Science Institute. She holds a Masters Degree in Cellular and Developmental Biology from Harvard University and an MD from Harvard Medical School. She completed her residency in internal medicine at the Peter Bent Brigham Hospital and completed a fellowship in cardiovascular medicine at the Johns Hopkins University Medical Center. She currently serves on the NHLBI Board of External Experts and the NHLBI Protocol Review Committee, Cardiovascular Cell Therapy, Research Network, and the AHA National Research Committee. Dr. Hochman was recently executive chair, NHLBI Cardiovascular Disease Executive Strategic Planning Committee; co-chair, NHLBI Strategic Planning Clinical Trials Working Group; and member, NHLBI Strategic Planning CAD Working Group. She is a member of the American College of Cardiology/AHA (ACC/AHA) Task Force on Practice Guidelines and was recently a member of the Guideline Writing Committees for both the Non-ST Elevation MI/Unstable Angina and Acute ST Elevation Myocardial Infarction Guidelines. She is a senior guest editor for Circulation and serves on the editorial boards of Circulation, European Heart Journal, American Heart Journal, Acute Cardiac Care, Critical Pathways in Cardiology, and Chest Pain on Line. She is the author of chapters in Harrison's Textbook of Internal Medicine, Topol's Textbook of Cardiovascular Medicine and editor of an AHA textbook on cardiogenic shock in their new AHA Clinical Series. Dr. Hochman was elected to the Association of University Cardiologists and the Association of American Physicians. She has authored over 200 publications. Dr. Hochman has served as a mentor for numerous trainees and has achieved national recognition as a mentor, as evidenced by her receipt of the 2008 AHA Women in Cardiology Mentoring Award. 

Dr. Hochman is an experienced clinical trialist and has a particular interest in ischemic hearts disease, including the study of optimal management strategies, sex differences in pathophysiology and response to treatment, and cardiogenic shock. She developed, organized, was awarded NHLBI funding for, and was the study chair and director of the Clinical Coordinating Center SHOCK Trial and Registry. The SHOCK Trial demonstrated the survival benefit of early revascularization for cardiogenic shock due to LV failure complicating myocardial infarction; these results led directly to revisions of the ACC/AHA Guidelines on the management of myocardial infarction. She also developed, organized, and was Study Chair for the first phase 2 and phase 3 multicenter randomized trials conducted to test a pharmacologic agent, a nitric oxide synthase inhibitor, for cardiogenic shock complicating acute MI (SHOCK 2 and TRIUMPH). Dr. Hochman also developed and led an NHLBI-funded international trial of late angioplasty/stenting after myocardial infarction, the Occluded Artery Trial (OAT). She is study chair and PI of OAT and directs the Clinical Coordinating Center at NYU involving over 200 sites, five core laboratories and other coordinating centers around the world. The results, which demonstrated no benefit for late angioplasty for persistent total occlusion late post MI and a trend toward excess reinfarction, were reported in the NEJM, and have resulted in new recommendations in the 2007 ACC/AHA guidelines on Unstable Angina/NSTEMI and ST Elevation Myocardial Infarction and the 2008 European Society of Cardiology Guidelines on STEMI. She has expertise in the investigation of novel anti-platelet and anticoagulant agent use in ACS and has served on the steering committee and Data Safety Monitoring Board for numerous international clinical trials testing these agents.